Binimetinib

Binimetinib (**MEK162**, **ARRY-162**) is a MEK inhibitor being developed by Array Biopharma to treat various cancers.[1]

It can be taken orally in tablet form.[2]

In 2015 it was in phase 3 clinical trials for ovarian cancer,[3] BRAF mutant melanoma,[4] and NRAS Q61 mutant melanoma.[2]

In Dec 2015 the company announced that the mutant-NRAS melanoma trial was successful.[5] In the trial, those receiving binimetinib had a median progression-free survival of 2.8 months versus 1.5 months for those on the standard dacarbazine treatment.[6] NDA submitted Jun 2016,[7] and the FDA should decide by 30 June 2017.[8]

In April 2016 it was reported that the phase III trial for low-grade ovarian cancer was terminated due to lack of efficacy.[9]

1 References

[1] "Array biopharma:: Binimetinib"

[2] Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

[3] A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

[4] Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

[5] Array BioPharma Has Successful Trial for Cancer Drug Binimetinib. Dec 2015

[6] Array BioPharma announces Phase 3 binimetinib trial meets primary endpoint for NRAS-mutant melanoma. Dec 2015

[7] Array Bio submits marketing application in U.S. for lead product candidate in certain type of melanoma. June 2016

[8] FDA accepts Array Bio's NDA for binimetinib, action date June 30; Sept 2016

[9] Array bags Phase 3 study of binimetinib in ovarian cancer; shares down 4%

2 Text and image sources, contributors, and licenses

2.1 Text

- **Binimetinib** *Source:* https://en.wikipedia.org/wiki/Binimetinib?oldid=747344031 *Contributors:* DePiep, Rod57, The chemistds, Louisajb, Teaktl17, Frietjes, Vaccinationist, Gtpase and BiomolecularGraphics4All

2.2 Images

- **File:Cisplatin-3D-vdW.png** *Source:* https://upload.wikimedia.org/wikipedia/commons/7/77/Cisplatin-3D-vdW.png *License:* Public domain *Contributors:* Own work *Original artist:* Benjah-bmm27

2.3 Content license

- Creative Commons Attribution-Share Alike 3.0